Aspirin resistance in patients taking small dose of aspirin

Chinese Critical Care Medicine

Volumn 18, Issue 4, 2006, Pages 219-223

  Wang, Chun Bo ^a   Hu, Da Yi ^a   Shi, Xu Bo ^a   Zhu, Zheng Yan ^a   Zhu, Jing Yan ^a   Yang, Jin Gang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin; Cardiac and cerebral vascular disease; Platelet aggregation; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID;

AGED; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HEART DISEASE; HUMAN; HUMAN CELL; HYPERTENSION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOMENOLOGY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 33646544696     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Anonymous. Collaborative overview of randomized trials of antiplatelet therapy-I-III [J]. BMJ, 1994, 308 (6921-6923): 81-106, 159-168, 235-246.
2. Helgason C M, Bolin K M, Hoff J A, et al. Development of aspirin resistance in persons with previous ischemic stroke [J]. Stroke, 1994, 25: 2331-2336.
3. Pappas J M, Westengard J C, Bull B S. Population variability in the effect of aspirin on platelet function: implication for clinical trials and therapy [J]. Arch Pathol Lab Med, 1994, 118: 801-804.
4. Grotemeyer K H, Scharafinski H W, Husstedt I W. Two-year follow-up of aspirin responder and aspirin non-responder: a pilot-study including 180 post-stroke patients [J]. Thromb Res, 1993, 71: 397-403.
5. Gum P A, Kotike-Marchant K, Poggio E D, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease [J]. Am J Cardiol, 2001, 88: 230-235.
6. Gum P A, Kottke-Marchant K, Welsh P A, et al. A Prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease [J]. J Am Coll Cardiol, 2003, 41: 961-965.
7. Lee P Y, Chen W H, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease [J]. Am J Med, 2005, 118: 723-727.
8. Valles J, Santos M T, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-does is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity [J]. Circulation, 1998, 97: 350-355.
9. Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage [J]? Thromb Res, 1998, 92: s7-s12.
10. Taylor D W, Barnett H J, Haynes R B, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) trial collaborators [J]. Lancet, 1999, 353: 2179-2184.
11. Morrow J D. The isoprostanes: their quantification as an index of oxidant stress status in vivo [J]. Drug Metab Rev, 2000, 32: 377-385.
12. Albert S G, Hasnain B I, Ritter D G, et al. Aspirin sensitivity of platelet aggregation in diabetes mellitus [J]. Diabetes Res Clin Pract, 2005, 70: 195-199.
13. Davis J W, Hartman C R, Lewis H D Jr, et al. Cigarette smoking-induced enchancement of platelet function: lack of prevention by aspirin in men with coronary artery disease [J]. J Lab Clin Med, 1985, 105: 479-483.
14. Davis J W, Davis R F, Hassanein K M. In healthy habitual smokers acctylsalicyclic acid abolishes the effects of tobacco smoke on the platelet aggregate ratio [J]. Can Med Assoc J, 1982, 126: 637-639.
15. Valles J, Santos M T, Aznar J, et al. Erythrocyte metabolically enhance collagen-induced platelet responsiveness Nia increased thromboxane production, adenosine diphosphate release, and recruitment [J]. Blood, 1991, 78: 154-162.
16. Eikelboom J W, Hirsh J, Weitz J I, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events [J]. Circulation, 2002, 105: 1650-1655.
17. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high - risk patients: the heart outcomes prevention evaluation study investigators [J]. N Engl J Med, 2000, 342: 154-160.
18. Yusuf S, Zhao F, Mehta S R, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation: the clopidogrel in unstable angina to prevent recurrent events trial investigators [J]. N Engl J Med, 2001, 345: 494-502.
19. Mehta S R, Yusuf S, Peters R J, et al. Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI - CURE study [J]. Lancet, 2001, 358: 527-533.
20. Steinhubl S R, Berger P B, Mann J T 3rd, et al. CREDO investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [J]. JAMA, 2002, 288: 2411-2420.